Merck extends gains after data for COVID-19 pill as vaccine makers retreat

seekingalpha2021-10-04

After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands. Meantime, the established vaccine ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

KH321
2021-10-06
KH321
OK
PML318
2021-10-05
PML318
ok
- PML318:
  ok
Nez
2021-10-05
Nez
Good
Zified
2021-10-05
Zified
Ok
AlexReddySG
2021-10-05
AlexReddySG
Good for the world
- Zified:
  Ok
Mm101
2021-10-05
Mm101
Ff

发表看法

147

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1140558350?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-04 21:46","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1140558350","market":"us","top_or_hot":-1,"title":"Merck extends gains after data for COVID-19 pill as vaccine makers retreat","media":"seekingalpha","content":"<div>\n<p>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck extends gains after data for COVID-19 pill as vaccine makers retreat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck extends gains after data for COVID-19 pill as vaccine makers retreat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat","article_id":"1140558350","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140558350","pubTimestamp":1633355202,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-mark","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","MRK":"默沙东","MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"translate_title":"随着疫苗制造商撤退，新冠肺炎药丸数据公布后，默沙东扩大了收益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9,"MRK":0.9,"MRNA":0.9,"NVAX":0.9,"PFE":0.9},"content_text":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.\nIn an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.\nModerna (MRNA) and BioNTech (BNTX) are notable decliners, trading ~5.1% and ~6.0% lower, while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has lost ~6.3% after sliding ~26.8% last week to rank among the worst performers in healthcare.\nHowever, Pfizer (PFE) and Johnson & Johnson(NYSE:JNJ)are trading flat, with losses standing at ~0.8% and ~0.1% in the pre-market.\nPfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.\nMeanwhile,TheNew York Times reported today that Johnson & Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":829668641,"gmtCreate":1633500388676,"gmtModify":1633500389116,"author":{"id":"3586451610703869","authorId":"3586451610703869","name":"KH321","avatar":"https://static.tigerbbs.com/c1bb8bd7d6d5df5f9732871fe60999ea","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3586451610703869","idStr":"3586451610703869"},"htmlText":"OK","listText":"OK","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829668641","repostId":1140558350,"repostType":4,"repost":{"id":"1140558350","kind":"news","pubTimestamp":1633355202,"share":"https://www.laohu8.com/m/news/1140558350?lang=&edition=full","pubTime":"2021-10-04 21:46","market":"us","language":"en","title":"Merck extends gains after data for COVID-19 pill as vaccine makers retreat","url":"https://stock-news.laohu8.com/highlight/detail?id=1140558350","media":"seekingalpha","summary":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-mark","content":"<ul>\n <li>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading&nbsp;~4.0% higher,&nbsp;with ~1.8 million shares changing hands.</li>\n <li>Meantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.</li>\n <li>In an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.</li>\n <li>Moderna (MRNA) and BioNTech (BNTX) are notable decliners, trading&nbsp;~5.1% and ~6.0% lower,&nbsp;while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has&nbsp;lost ~6.3%&nbsp;after sliding ~26.8% last week to rank among the&nbsp;worst performers in healthcare.</li>\n <li>However, Pfizer (PFE) and Johnson &amp; Johnson(NYSE:JNJ)are trading flat, with&nbsp;losses standing at ~0.8% and ~0.1%&nbsp;in the pre-market.</li>\n <li>Pfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.</li>\n <li>Meanwhile,<i>TheNew York Times</i>&nbsp;reported today that Johnson &amp; Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck extends gains after data for COVID-19 pill as vaccine makers retreat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck extends gains after data for COVID-19 pill as vaccine makers retreat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRK":"默沙东"},"source_url":"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140558350","content_text":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.\nIn an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.\nModerna (MRNA) and BioNTech (BNTX) are notable decliners, trading ~5.1% and ~6.0% lower, while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has lost ~6.3% after sliding ~26.8% last week to rank among the worst performers in healthcare.\nHowever, Pfizer (PFE) and Johnson & Johnson(NYSE:JNJ)are trading flat, with losses standing at ~0.8% and ~0.1% in the pre-market.\nPfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.\nMeanwhile,TheNew York Times reported today that Johnson & Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820488368,"gmtCreate":1633416298294,"gmtModify":1633416298584,"author":{"id":"3580696826076595","authorId":"3580696826076595","name":"PML318","avatar":"https://static.tigerbbs.com/9b82bd72b5f7a18185b472a15230a1e7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3580696826076595","idStr":"3580696826076595"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820488368","repostId":1140558350,"repostType":4,"repost":{"id":"1140558350","kind":"news","pubTimestamp":1633355202,"share":"https://www.laohu8.com/m/news/1140558350?lang=&edition=full","pubTime":"2021-10-04 21:46","market":"us","language":"en","title":"Merck extends gains after data for COVID-19 pill as vaccine makers retreat","url":"https://stock-news.laohu8.com/highlight/detail?id=1140558350","media":"seekingalpha","summary":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-mark","content":"<ul>\n <li>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading&nbsp;~4.0% higher,&nbsp;with ~1.8 million shares changing hands.</li>\n <li>Meantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.</li>\n <li>In an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.</li>\n <li>Moderna (MRNA) and BioNTech (BNTX) are notable decliners, trading&nbsp;~5.1% and ~6.0% lower,&nbsp;while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has&nbsp;lost ~6.3%&nbsp;after sliding ~26.8% last week to rank among the&nbsp;worst performers in healthcare.</li>\n <li>However, Pfizer (PFE) and Johnson &amp; Johnson(NYSE:JNJ)are trading flat, with&nbsp;losses standing at ~0.8% and ~0.1%&nbsp;in the pre-market.</li>\n <li>Pfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.</li>\n <li>Meanwhile,<i>TheNew York Times</i>&nbsp;reported today that Johnson &amp; Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck extends gains after data for COVID-19 pill as vaccine makers retreat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck extends gains after data for COVID-19 pill as vaccine makers retreat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRK":"默沙东"},"source_url":"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140558350","content_text":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.\nIn an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.\nModerna (MRNA) and BioNTech (BNTX) are notable decliners, trading ~5.1% and ~6.0% lower, while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has lost ~6.3% after sliding ~26.8% last week to rank among the worst performers in healthcare.\nHowever, Pfizer (PFE) and Johnson & Johnson(NYSE:JNJ)are trading flat, with losses standing at ~0.8% and ~0.1% in the pre-market.\nPfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.\nMeanwhile,TheNew York Times reported today that Johnson & Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6097969,"gmtCreate":1633416311892,"gmtModify":1634721495216,"authorId":3580696826076595,"author":{"id":3580696826076595,"idStr":"3580696826076595","authorId":3580696826076595,"name":"PML318","avatar":"https://static.tigerbbs.com/9b82bd72b5f7a18185b472a15230a1e7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820488368,"type":1,"supId":0,"prevId":0,"content":"<p>ok</p>","text":"<p>ok</p>","html":"<p>ok</p>"}],"langContent":"CN"},{"id":820496823,"gmtCreate":1633411548676,"gmtModify":1633411549452,"author":{"id":"3577664011514694","authorId":"3577664011514694","name":"Nez","avatar":"https://static.tigerbbs.com/b32d6842fa474340581d116936497abb","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3577664011514694","idStr":"3577664011514694"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820496823","repostId":1140558350,"repostType":4,"repost":{"id":"1140558350","kind":"news","pubTimestamp":1633355202,"share":"https://www.laohu8.com/m/news/1140558350?lang=&edition=full","pubTime":"2021-10-04 21:46","market":"us","language":"en","title":"Merck extends gains after data for COVID-19 pill as vaccine makers retreat","url":"https://stock-news.laohu8.com/highlight/detail?id=1140558350","media":"seekingalpha","summary":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-mark","content":"<ul>\n <li>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading&nbsp;~4.0% higher,&nbsp;with ~1.8 million shares changing hands.</li>\n <li>Meantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.</li>\n <li>In an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.</li>\n <li>Moderna (MRNA) and BioNTech (BNTX) are notable decliners, trading&nbsp;~5.1% and ~6.0% lower,&nbsp;while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has&nbsp;lost ~6.3%&nbsp;after sliding ~26.8% last week to rank among the&nbsp;worst performers in healthcare.</li>\n <li>However, Pfizer (PFE) and Johnson &amp; Johnson(NYSE:JNJ)are trading flat, with&nbsp;losses standing at ~0.8% and ~0.1%&nbsp;in the pre-market.</li>\n <li>Pfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.</li>\n <li>Meanwhile,<i>TheNew York Times</i>&nbsp;reported today that Johnson &amp; Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck extends gains after data for COVID-19 pill as vaccine makers retreat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck extends gains after data for COVID-19 pill as vaccine makers retreat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRK":"默沙东"},"source_url":"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140558350","content_text":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.\nIn an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.\nModerna (MRNA) and BioNTech (BNTX) are notable decliners, trading ~5.1% and ~6.0% lower, while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has lost ~6.3% after sliding ~26.8% last week to rank among the worst performers in healthcare.\nHowever, Pfizer (PFE) and Johnson & Johnson(NYSE:JNJ)are trading flat, with losses standing at ~0.8% and ~0.1% in the pre-market.\nPfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.\nMeanwhile,TheNew York Times reported today that Johnson & Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820574167,"gmtCreate":1633409370593,"gmtModify":1633409371087,"author":{"id":"3575931476822699","authorId":"3575931476822699","name":"Zified","avatar":"https://static.tigerbbs.com/2504476ab9db7b38867d7694e9c634e7","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3575931476822699","idStr":"3575931476822699"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820574167","repostId":1140558350,"repostType":4,"repost":{"id":"1140558350","kind":"news","pubTimestamp":1633355202,"share":"https://www.laohu8.com/m/news/1140558350?lang=&edition=full","pubTime":"2021-10-04 21:46","market":"us","language":"en","title":"Merck extends gains after data for COVID-19 pill as vaccine makers retreat","url":"https://stock-news.laohu8.com/highlight/detail?id=1140558350","media":"seekingalpha","summary":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-mark","content":"<ul>\n <li>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading&nbsp;~4.0% higher,&nbsp;with ~1.8 million shares changing hands.</li>\n <li>Meantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.</li>\n <li>In an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.</li>\n <li>Moderna (MRNA) and BioNTech (BNTX) are notable decliners, trading&nbsp;~5.1% and ~6.0% lower,&nbsp;while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has&nbsp;lost ~6.3%&nbsp;after sliding ~26.8% last week to rank among the&nbsp;worst performers in healthcare.</li>\n <li>However, Pfizer (PFE) and Johnson &amp; Johnson(NYSE:JNJ)are trading flat, with&nbsp;losses standing at ~0.8% and ~0.1%&nbsp;in the pre-market.</li>\n <li>Pfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.</li>\n <li>Meanwhile,<i>TheNew York Times</i>&nbsp;reported today that Johnson &amp; Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck extends gains after data for COVID-19 pill as vaccine makers retreat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck extends gains after data for COVID-19 pill as vaccine makers retreat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRK":"默沙东"},"source_url":"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140558350","content_text":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.\nIn an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.\nModerna (MRNA) and BioNTech (BNTX) are notable decliners, trading ~5.1% and ~6.0% lower, while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has lost ~6.3% after sliding ~26.8% last week to rank among the worst performers in healthcare.\nHowever, Pfizer (PFE) and Johnson & Johnson(NYSE:JNJ)are trading flat, with losses standing at ~0.8% and ~0.1% in the pre-market.\nPfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.\nMeanwhile,TheNew York Times reported today that Johnson & Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":820558558,"gmtCreate":1633406456052,"gmtModify":1633406456457,"author":{"id":"3571116462495160","authorId":"3571116462495160","name":"AlexReddySG","avatar":"https://static.tigerbbs.com/bde95343afe80089edcc768ef3e746af","vip":1,"crmLevel":8,"crmLevelSwitch":0,"authorIdStr":"3571116462495160","idStr":"3571116462495160"},"htmlText":"Good for the world","listText":"Good for the world","text":"Good for the world","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/820558558","repostId":1140558350,"repostType":4,"repost":{"id":"1140558350","kind":"news","pubTimestamp":1633355202,"share":"https://www.laohu8.com/m/news/1140558350?lang=&edition=full","pubTime":"2021-10-04 21:46","market":"us","language":"en","title":"Merck extends gains after data for COVID-19 pill as vaccine makers retreat","url":"https://stock-news.laohu8.com/highlight/detail?id=1140558350","media":"seekingalpha","summary":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-mark","content":"<ul>\n <li>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading&nbsp;~4.0% higher,&nbsp;with ~1.8 million shares changing hands.</li>\n <li>Meantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.</li>\n <li>In an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.</li>\n <li>Moderna (MRNA) and BioNTech (BNTX) are notable decliners, trading&nbsp;~5.1% and ~6.0% lower,&nbsp;while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has&nbsp;lost ~6.3%&nbsp;after sliding ~26.8% last week to rank among the&nbsp;worst performers in healthcare.</li>\n <li>However, Pfizer (PFE) and Johnson &amp; Johnson(NYSE:JNJ)are trading flat, with&nbsp;losses standing at ~0.8% and ~0.1%&nbsp;in the pre-market.</li>\n <li>Pfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.</li>\n <li>Meanwhile,<i>TheNew York Times</i>&nbsp;reported today that Johnson &amp; Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck extends gains after data for COVID-19 pill as vaccine makers retreat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck extends gains after data for COVID-19 pill as vaccine makers retreat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRK":"默沙东"},"source_url":"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140558350","content_text":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.\nIn an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.\nModerna (MRNA) and BioNTech (BNTX) are notable decliners, trading ~5.1% and ~6.0% lower, while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has lost ~6.3% after sliding ~26.8% last week to rank among the worst performers in healthcare.\nHowever, Pfizer (PFE) and Johnson & Johnson(NYSE:JNJ)are trading flat, with losses standing at ~0.8% and ~0.1% in the pre-market.\nPfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.\nMeanwhile,TheNew York Times reported today that Johnson & Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6097277,"gmtCreate":1633409376285,"gmtModify":1634721552630,"authorId":3575931476822699,"author":{"id":3575931476822699,"idStr":"3575931476822699","authorId":3575931476822699,"name":"Zified","avatar":"https://static.tigerbbs.com/2504476ab9db7b38867d7694e9c634e7","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":820558558,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":820581451,"gmtCreate":1633402614217,"gmtModify":1633402739149,"author":{"id":"3565081661382277","authorId":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3565081661382277","idStr":"3565081661382277"},"htmlText":"Ff","listText":"Ff","text":"Ff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/820581451","repostId":1140558350,"repostType":4,"repost":{"id":"1140558350","kind":"news","pubTimestamp":1633355202,"share":"https://www.laohu8.com/m/news/1140558350?lang=&edition=full","pubTime":"2021-10-04 21:46","market":"us","language":"en","title":"Merck extends gains after data for COVID-19 pill as vaccine makers retreat","url":"https://stock-news.laohu8.com/highlight/detail?id=1140558350","media":"seekingalpha","summary":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-mark","content":"<ul>\n <li>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading&nbsp;~4.0% higher,&nbsp;with ~1.8 million shares changing hands.</li>\n <li>Meantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.</li>\n <li>In an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.</li>\n <li>Moderna (MRNA) and BioNTech (BNTX) are notable decliners, trading&nbsp;~5.1% and ~6.0% lower,&nbsp;while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has&nbsp;lost ~6.3%&nbsp;after sliding ~26.8% last week to rank among the&nbsp;worst performers in healthcare.</li>\n <li>However, Pfizer (PFE) and Johnson &amp; Johnson(NYSE:JNJ)are trading flat, with&nbsp;losses standing at ~0.8% and ~0.1%&nbsp;in the pre-market.</li>\n <li>Pfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.</li>\n <li>Meanwhile,<i>TheNew York Times</i>&nbsp;reported today that Johnson &amp; Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck extends gains after data for COVID-19 pill as vaccine makers retreat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck extends gains after data for COVID-19 pill as vaccine makers retreat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","MRK":"默沙东"},"source_url":"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140558350","content_text":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.\nIn an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.\nModerna (MRNA) and BioNTech (BNTX) are notable decliners, trading ~5.1% and ~6.0% lower, while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has lost ~6.3% after sliding ~26.8% last week to rank among the worst performers in healthcare.\nHowever, Pfizer (PFE) and Johnson & Johnson(NYSE:JNJ)are trading flat, with losses standing at ~0.8% and ~0.1% in the pre-market.\nPfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.\nMeanwhile,TheNew York Times reported today that Johnson & Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":147,"commentSize":30,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140558350"}